Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients
Journal of Clinical Immunology · 2024
DOI: 10.1007/s10875-024-01708-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Ami Aoki und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. Hauptthemen laut MEDLINE: Autoantibodies, COVID-19, Interferon Type I, Myeloid Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology (MEXT Japan) Grants-in-Aid for Scientific Research, Transformative Research Areas, Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from the Japan Agency for Medical Research and D….
Abstract (Originalsprache)
Purpose
Auto-antibodies (auto-abs) to type I interferons (IFNs) have been identified in patients with life-threatening coronavirus disease 2019 (COVID-19), suggesting that the presence of auto-abs may be a risk factor for disease severity. We therefore investigated the mechanism underlying COVID-19 exacerbation induced by auto-abs to type I IFNs.
Methods
We evaluated plasma from 123 patients with COVID-19 to measure auto-abs to type I IFNs. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells from the patients with auto-abs and conducted epitope mapping of the auto-abs.
Results
Three of 19 severe and 4 of 42 critical COVID-19 patients had neutralizing auto-abs to type I IFNs. Patients with auto-abs to type I IFNs showed no characteristic clinical features. scRNA-seq from 38 patients with COVID-19 revealed that IFN signaling in conventional dendritic cells and canonical monocytes was attenuated, and SARS-CoV-2-specific BCR repertoires were decreased in patients with auto-abs. Furthermore, auto-abs to IFN-α2 from COVID-19 patients with auto-abs recognized characteristic epitopes of IFN-α2, which binds to the receptor.
Conclusion
Auto-abs to type I IFN found in COVID-19 patients inhibited IFN signaling in dendritic cells and monocytes by blocking the binding of type I IFN to its receptor. The failure to properly induce production of an antibody to SARS-CoV-2 may be a causative factor of COVID-19 severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
- Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
- Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
- Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, 113-8431, Japan.
- Funabashi Central Hospital, Chiba, 273-8556, Japan.
ORCID-Profile: Kiyoshi Hirahara
Förderung
- Ministry of Education, Culture, Sports, Science and Technology (MEXT Japan) Grants-in-Aid for Scientific Research
- Transformative Research Areas
- Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from the Japan Agency for Medical Research and D…
- AMED-PRIME
- AMED-CREST
- JST FOREST Project
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- MSD Life Science Foundation, Public Interest Incorporated Foundation
Zitieren
APA
Aoki, A., Iwamura, C., Kiuchi, M., Tsuji, K., Sasaki, A., Hishiya, T., Hirasawa, R., Kokubo, K., Kuriyama, S., Onodera, A., Shimada, T., Nagaoka, T., Ishikawa, S., Kojima, A., Mito, H., Hase, R., Kasahara, Y., Kuriyama, N., Nakamura, S., …, & Hirahara, K. (2024). Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01708-7
Vancouver
Aoki A, Iwamura C, Kiuchi M, Tsuji K, Sasaki A, Hishiya T, et al. Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01708-7
BibTeX
@article{Aoki2024,
author = {Aoki, Ami and Iwamura, Chiaki and Kiuchi, Masahiro and Tsuji, Kaori and Sasaki, Atsushi and Hishiya, Takahisa and Hirasawa, Rui and Kokubo, Kota and Kuriyama, Sachiko and Onodera, Atsushi and Shimada, Tadanaga and Nagaoka, Tetsutaro and Ishikawa, Satoru and Kojima, Akira and Mito, Haruki and Hase, Ryota and Kasahara, Yasunori and Kuriyama, Naohide and Nakamura, Sukeyuki and Urushibara, Takashi and Kaneda, Satoru and Sakao, Seiichiro and Nishida, Osamu and Takahashi, Kazuhisa and Kimura, Motoko Y and Motohashi, Shinichiro and Igari, Hidetoshi and Ikehara, Yuzuru and Nakajima, Hiroshi and Suzuki, Takuji and Hanaoka, Hideki and Nakada, Taka-Aki and Kikuchi, Toshiaki and Nakayama, Toshinori and Yokote, Koutaro and Hirahara, Kiyoshi},
title = {Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients},
journal = {Journal of Clinical Immunology},
year = {2024},
doi = {10.1007/s10875-024-01708-7}
}
EUVIMED